ENDRA Life Sciences (NASDAQ:NDRA) Trading 3.3% Higher – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price traded up 3.3% during mid-day trading on Tuesday . The company traded as high as $5.13 and last traded at $4.95. 10,183 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 47,782 shares. The stock had previously closed at $4.79.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NDRA. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. Ascendiant Capital Markets decreased their price objective on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ENDRA Life Sciences has an average rating of “Hold” and a consensus price target of $25.00.

ENDRA Life Sciences Price Performance

The company’s 50 day simple moving average is $5.04 and its 200 day simple moving average is $4.57. The company has a market capitalization of $6.29 million, a PE ratio of -0.61 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Friday, May 15th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.14. On average, equities analysts forecast that ENDRA Life Sciences Inc. will post -4.11 EPS for the current year.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for approximately 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th largest holding. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences as of its most recent SEC filing. 1.19% of the stock is currently owned by hedge funds and other institutional investors.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.